← All trials
NCT05569720
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 25, 2022
- Primary completion
- Jun 24, 2022
- Completion date
- Jun 24, 2022
- First posted
- Oct 6, 2022
- Last posted
- Oct 6, 2022
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- aptaTargets S.L.Lead sponsor
- Universidad Autonoma de MadridOverall official - principal investigator
- aptaTargets S.L.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.